UBS raised the firm’s price target on CME Group (CME) to $310 from $280 and keeps a Neutral rating on the shares. CME has seen strong year-to-date performance, supported by elevated trading volumes amid renewed market volatility, the analyst tells investors in a research note. Growth is being bolstered by new initiatives, including recently launched event contracts and the FanDuel partnership, the firm says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- Crypto Currents: Bitcoin plunges below $68,000 amid liquidation cascade
- CME Group price target raised to $302 from $295 at RBC Capital
- CME Group price target raised to $266 from $262 at JPMorgan
- CME Group price target raised to $328 from $305 at TD Cowen
- CME Group price target raised to $340 from $319 at Morgan Stanley